TITLE

News Briefs

PUB. DATE
June 2010
SOURCE
American Journal of Health-System Pharmacy;6/15/2010, Vol. 67 Issue 12, p964
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. including one related to the addition of pharmacists in patient-centered medical homes and another related to the approval of the Alair bronchial thermoplasty from Asthmatx Inc. system by the U.S. Food and Drug Administration (FDA).
ACCESSION #
51219033

 

Related Articles

  • DDMAC enforcement letters skyrocket. J. G. D. // Medical Marketing & Media;Nov2010, Vol. 45 Issue 11, p30 

    The article reports on the increasing number of letters sent by the U.S. Food and Drug Administration (FDA) that warn pharmaceutical marketers who violate agency advertising and promotion regulations.

  • As I See It. Thacker, Paul D. // Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p26 

    The article presents the author's views on the move of the pharmaceutical industry to pressure the U.S. Congress and the Food and Drug Administration (FDA) regarding the conflict-of-interest on safety rules.

  • So Little Time - So Much To Do. Auerbach, Michael // Pharmaceutical Processing;Jan2009, Vol. 24 Issue 1, p6 

    The article discusses the report published within this issue by John Avellanet on the business, regulatory and manufacturing issues that the U.S. Food and Drug Administration (FDA) will consider for the pharmaceutical industry in 2009.

  • Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution. Kux, Leslie // Federal Register (National Archives & Records Service, Office of;10/24/2011, Vol. 76 Issue 205, p65730 

    The article presents a notice from the U.S. Food and Drug Administration (FDA) on the proposed requirement governing the registration of drug manufacturers and the listing of drugs in commercial distribution.

  • FDA, Industry Hit Impasse on Waivers.  // BioWorld Today;3/21/2011, Vol. 22 Issue 54, p6 

    This article reports on the impasse reached between the U.S. Food and Drug Administration (FDA) and the drug industry on how affiliates should be handled in determining user fee waivers for small businesses.

  • FDA's Transparency Efforts.  // BioWorld Today;10/20/2011, Vol. 22 Issue 204, p5 

    The article explores the failure of transparency efforts of the U.S. Food and Drug Administration regarding the performance goals and drugs developed by the pharmaceutical companies.

  • WEEK IN WASHINGTON.  // BioWorld Insight;5/30/2011, Vol. 19 Issue 22, p6 

    The article offers news briefs related to the pharmaceutical industry in the U.S. which include the introduction of the Qualifying Therapeutic Discovery Project Tax Credit Extension Act by U.S. Representatives Susan Davis, and Allyson Schwartz, and the establishment of a case for more disclosure...

  • WEEK IN WASHINGTON.  // BioWorld Insight;4/5/2010, Vol. 18 Issue 14, p5 

    The article offers news briefs related to pharmaceutical industry in the U.S. including the invalidation of the federal district court judge on Myriad Genetics Inc.'s patent claims on BRCA1 and 2 genes and the issuance of the Food and Drug Administration's (FDA) final guidance on dosage.

  • Retrospection and Introspection at FDA. Hoffman, Michelle // BioPharm International;Sep2011, Vol. 24 Issue 9, p8 

    An introduction is presented in which the editor discusses a report from the U.S. Food and Drug Administration (FDA) on quality-by-design (QbD) initiative in the pharmaceutical industry.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics